These deals come amid a surge in ADC dealmaking across the pharmaceutical sector. Credit: izusek via Getty Images. Lonza’s subsidiary Synaffix has secured licensing agreements
Verdiva aims to advance a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Credit: Nuthawut Somsuk via Getty Images. As the
The companies have teamed up to use Alloy’s AntiClastic Antisense platform. Credit: Bevan Goldswain via Getty Images. Sanofi has entered into a collaboration and license
The companies will focus on next-generation gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. Credit: da-kuk via Getty Images. Vertex Pharmaceuticals and Orna
Image credit: Getty Images/ sefa ozel US-based Acelyrin reported positive Phase II data for its monoclonal antibody lonigutamab in thyroid eye disease (TED), but was
The Dundalk site provides drug substance and product manufacturing, as well as quality control capabilities. Credit: Comezora via Getty Images. WuXi Biologics subsidiary WuXi Vaccines
The funds will support the development of Orbis’ pipeline of next-generation oral macrocycle drugs. Credit: sanjeri via Getty Images. Denmark-based biotech Orbis Medicines has raised
Evkeeza is the first medicine indicated for children in the EU as young as six months old to treat HoFH. Credit: FatCamera via Shutterstock. The
Shares in Sangamo lost 50% of their value in after-hours trading following the announcement, which came just before the close on 30 December. Credit: jayk7
OSA is usually treated with a mask worn during sleep, called a continuous positive airway pressure (CPAP) machine. Credit: Kateryna Mostova via Shutterstock. Eli Lilly’s